Funded Startups in Lausanne
Across the 50 most recent rounds listed for Lausanne, the largest disclosed amount is ReproNovo’s $65M (2025-05-21) alongside another $65M for HAYA Therape…
Across the 50 most recent rounds listed for Lausanne, the largest disclosed amount is ReproNovo’s $65M (2025-05-21) alongside another $65M for HAYA Therapeutics (2025-05-08). That $65M ceiling dwarfs most other disclosed checks in the table, where multiple entries cluster far lower (for example $24M for Corintis on 2025-09-27, $27M for Neural Concept on 2024-06-03, and $50M for AC Immune on 2023-12-15). At the same time, the smallest disclosed amount shown is SensArs’ $30K (2024-09-06), creating a wide disclosed range between $30K and $65M.
The timing shows a dense mid-2024 cluster: many rounds share the 2024-02-09 date (multiple AI, biotech, health care, manufacturing, energy), and several more run through late 2024 into early 2025, spanning 2023-06-13 (Abionic) through 2025-10-19 (BehaviorSMART). Sector-wise, biotech appears in 10 entries, while AI appears in 8; meanwhile amounts are undisclosed for 9 entries and “Series Unknown” appears in 18 rows, indicating that stage and deal size visibility is uneven across the same city label (Lausanne, Vaud).
Most recent rounds
50 shownRelated listings
Frequently asked
What stands out in disclosed round sizes across these Lausanne rounds?
The largest disclosed check is $65M, held by ReproNovo (2025-05-21) and matched by HAYA Therapeutics (2025-05-08). That range sits above most other disclosed amounts such as Timeline ($65M on 2024-01-17), AC Immune ($50M on 2023-12-15), and Corintis ($24M on 2025-09-27), while the smallest disclosed amount is SensArs at $30K (2024-09-06).
Do any date windows show unusually dense activity?
Yes. Multiple entries close on the same date, most notably 2024-02-09, where several companies are listed with undisclosed amounts across categories including AI (Artifact), biotech (GenKnowme), health care (DomoHealth), manufacturing (Flybotix), and energy (TreaTech). Beyond that, the table extends from 2023-06-13 (Abionic) to 2025-10-19 (BehaviorSMART), with several rounds concentrated in late 2024 and early 2025 (e.g., 2024-07 through 2025-02).
Which stages dominate, and how often are stage labels unclear?
“Series Unknown” appears in 18 of the 50 rows, including Logmind (2025-08-11) and Brightside AI (2024-06-07), and undisclosed amounts also occur frequently (9 entries, e.g., BehaviorSMART on 2025-10-19 and Oryl Photonics on 2025-09-09). Disclosed, explicitly labeled rounds still include multiple Series A/B/D cases such as Corintis (Series A, $24M on 2025-09-27) and Neural Concept (Series B, $27M on 2024-06-03).
Are any sectors over-represented in this Lausanne slice?
Biotechnology is the most common sector with 10 entries (e.g., ReproNovo on 2025-05-21, HAYA Therapeutics on 2025-05-08, and Timeline on 2024-01-17), followed by Artificial Intelligence (8 entries such as miros on 2025-05-05, Neural Concept on 2024-06-03, and Atinary on 2023-09-26). Other sectors like Energy and Health Care appear but without the same density as biotech and AI in this list.
Are there deal-size outliers worth flagging for diligence?
At the low end, SensArs’ $30K (2024-09-06) is far below the bulk of disclosed rounds, where many checks are in the hundreds of thousands to low tens of millions (for example $480K for EarlySight on 2025-04-24 and $12M for Nanogence on 2023-10-19). At the high end, $65M rounds recur (ReproNovo 2025-05-21 and HAYA Therapeutics 2025-05-08), while several other large disclosed deals include Timeline at $65M (2024-01-17) and AC Immune at $50M (2023-12-15), making those companies prominent against the rest of the disclosed distribution.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.